No connection

Search Results

TCMD

NEUTRAL
$25.52 Live
Tactile Systems Technology, Inc. · NASDAQ
Target $38.0 (+48.9%)
$8.61 52W Range $37.77

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 21, 2026
Market cap
$580.59M
P/E
31.12
ROE
8.8%
Profit margin
5.8%
Debt/Equity
0.07
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
TCMD exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and an exceptionally strong balance sheet characterized by very low leverage (Debt/Equity 0.07). While the company shows robust revenue growth of 21% and high gross margins, the stock is currently trading at a premium to its Intrinsic Value ($24.19) and significantly above its Graham Number ($13.42). The valuation is further strained by an extreme PEG ratio of 17.79, suggesting the price has outpaced fundamental growth. Imminent regulatory risks regarding CMS Prior Authorization (PAR) requirements starting April 2026 and bearish insider activity create significant headwinds.

Key Strengths

Fortress balance sheet with very low Debt/Equity (0.07)
Excellent liquidity with a Current Ratio of 4.03
Strong top-line growth (21% YoY Revenue Growth)
High profitability potential with 75.91% Gross Margins
Consistent history of earnings surprises over the last 25 quarters

Key Risks

Regulatory risk: CMS Prior Authorization (PAR) requirements starting April 2026
Severe overvaluation relative to growth (PEG Ratio 17.79)
Bearish insider sentiment with consistent selling by CEO and CFO
High dependency on Medicare reimbursement and coverage criteria
Bearish technical trend (0/100)
AI Fair Value Estimate
Based on comprehensive analysis
$23.5
-7.9% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
48
Moderate
Value
30
Future
60
Past
65
Health
85
Dividend
0
AI Verdict
Stable but Overvalued
Key drivers: Balance Sheet Strength, Regulatory Headwinds, Valuation Gap
Confidence
80%
Value
30/100

Ref P/E 31.12, PEG 17.79, Graham $13.42

Positives
  • Forward P/E (17.30) is significantly lower than current P/E
Watchpoints
  • Price ($25.52) exceeds Intrinsic Value ($24.19)
  • Extreme PEG ratio (17.79)
  • Price is nearly double the Graham Number ($13.42)
Future
60/100

Ref Growth rates vs SEC Risk Factors

Positives
  • Strong 21% YoY revenue growth
  • Scalable home-care delivery model
Watchpoints
  • CMS PAR requirements may increase claim denials and delays
  • Potential for unfavorable NCD/LCD interpretations
Past
65/100

Ref Historical price and earnings trends

Positives
  • Strong 1Y price performance (+89.7%)
  • Frequent earnings beats
Watchpoints
  • Poor 5Y long-term performance (-55.1%)
Health
85/100

Ref Piotroski 4/9, Debt/Equity 0.07

Positives
  • Extremely low Debt/Equity (0.07)
  • High Current Ratio (4.03) and Quick Ratio (3.49)
Watchpoints
  • Piotroski F-Score is only 'Stable' (4/9)
Dividend
0/100

Ref Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend history or current yield

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$25.52
Analyst Target
$38.0
Upside/Downside
+48.9%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for TCMD and closest competitors.

Updated 2026-04-20
TCM
Tactile Systems Technology, Inc.
Primary
5Y
-55.1%
3Y
+37.4%
1Y
+89.7%
6M
+74.7%
1M
-2.2%
1W
+5.3%
MDX
MiMedx Group, Inc.
Peer
5Y
-67.5%
3Y
+18.4%
1Y
-42.1%
6M
-39.8%
1M
-10.5%
1W
+1.0%
LYE
Lyell Immunopharma, Inc.
Peer
5Y
-92.7%
3Y
-47.5%
1Y
+178.7%
6M
+47.4%
1M
+16.7%
1W
+14.3%
PRT
Prothena Corporation plc
Peer
5Y
-54.1%
3Y
-79.5%
1Y
+18.5%
6M
+9.9%
1M
+26.9%
1W
+3.8%
HST
HealthStream, Inc.
Peer
5Y
-8.4%
3Y
-25.8%
1Y
-36.2%
6M
-22.1%
1M
-3.1%
1W
-2.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
31.12
Forward P/E
17.3
PEG Ratio
17.79
P/B Ratio
2.62
P/S Ratio
1.76
EV/Revenue
1.53
EV/EBITDA
14.06
Market Cap
$580.59M

Profitability

Profit margins and return metrics

Profit Margin 5.79%
Operating Margin 18.12%
Gross Margin 75.91%
ROE 8.77%
ROA 6.4%

Growth

Revenue and earnings growth rates

Revenue Growth +21.0%
Earnings Growth +17.6%
Q/Q Revenue Growth +21.04%
Q/Q Earnings Growth +9.4%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.07
Low debt
Current Ratio
4.03
Strong
Quick Ratio
3.49
Excellent
Cash/Share
$3.72

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.1B
Gross Margin
78.2%
Op. Margin
18.1%
Net Margin
10.3%
Total Assets
$0.3B
Liabilities
$0.1B
Equity
$0.2B
Debt/Equity
0.25x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
97%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-04
$N/A
2026-02-17
$0.46
+3.4% surprise
2025-11-03
$0.36
+106.9% surprise
2025-08-04
$0.14
-3.5% surprise

Healthcare Sector Comparison

Comparing TCMD against 497 companies in the Healthcare sector (27 bullish, 153 neutral, 317 bearish)
P/E Ratio
31.12
This Stock
vs
84.2
Sector Avg
-63.0% (Discount)
Return on Equity (ROE)
8.77%
This Stock
vs
-95.56%
Sector Avg
-109.2% (Below Avg)
Profit Margin
5.79%
This Stock
vs
-15.89%
Sector Avg
-136.4% (Weaker)
Debt to Equity
0.07
This Stock
vs
2.89
Sector Avg
-97.5% (Less Debt)
Revenue Growth
21.0%
This Stock
vs
137.62%
Sector Avg
-84.7% (Slower)
Current Ratio
4.03
This Stock
vs
4.67
Sector Avg
-13.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

PEARSON ANDREA
Director
Stock Award
2026-03-09
852 shares
DODD SHERI LOUISE
Chief Executive Officer
Sell
2026-02-24
10,993 shares · $318,144
BURNS KRISTIE
Officer
Sell
2026-02-24
6,246 shares · $180,764
BIRKEMEYER ELAINE M
Chief Financial Officer
Sell
2026-02-24
7,701 shares · $222,880
DODD SHERI LOUISE
Chief Executive Officer
Sell
2026-02-23
15,240 shares · $431,245
BURNS KRISTIE
Officer
Sell
2026-02-23
4,439 shares · $125,612
BIRKEMEYER ELAINE M
Chief Financial Officer
Sell
2026-02-23
5,518 shares · $156,144
DODD SHERI LOUISE
Chief Executive Officer
Stock Award
2026-02-20
47,967 shares
BURNS KRISTIE
Officer
Stock Award
2026-02-20
14,671 shares
BIRKEMEYER ELAINE M
Chief Financial Officer
Stock Award
2026-02-20
25,919 shares
DODD SHERI LOUISE
Chief Executive Officer
Stock Award
2026-02-19
48,672 shares
BURNS KRISTIE
Officer
Stock Award
2026-02-19
6,194 shares
BIRKEMEYER ELAINE M
Chief Financial Officer
Stock Award
2026-02-19
23,008 shares
BURNS KRISTIE
Officer
Sell
2026-01-02
5,139 shares · $148,260
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A
DEF 14A
2026-03-25

TCMD filed a definitive proxy statement on March 25, 2026, providing shareholders with necessary information and voting materials for an upcoming meeting.

8-K
FORM 8-K
2026-03-09
10-K
10-K
2026-02-17

Tactile Systems Technology, Inc. (TCMD) provides medical devices for the at-home treatment of chronic vascular, oncology, and respiratory conditions. While specific financial metrics were not provided in the excerpts, the company focuses on a scalable home care delivery model designed to reduce healthcare expenditures. A primary risk to the business is the potential for changes to Medicare coverage or reimbursement criteria, which could adversely affect financial results.

8-K
8-K
2026-02-17

TCMD filed an 8-K on February 17, 2026, likely to announce its annual financial results or quarterly earnings.

10-Q
10-Q
2025-11-03

TCMD filed its 10-Q on November 3, 2025, though specific financial highlights were not provided in the available excerpt. The company reported no material changes to the risk factors previously disclosed in its Annual Report for the year ended December 31, 2024.

8-K
8-K
2025-11-03

TCMD likely filed this 8-K to report its third-quarter financial results.

10-Q
10-Q
2025-08-04

TCMD filed its quarterly report on August 4, 2025, noting that there have been no material changes to the risk factors previously disclosed in its 2024 Annual Report. No specific financial highlights were provided in the available excerpts.

8-K
8-K
2025-08-04

TCMD filed an 8-K on August 4, 2025, likely to report its second-quarter financial results.

8-K
FORM 8-K
2025-05-09
10-Q
10-Q
2025-05-05
8-K
8-K
2025-05-05

TCMD filed an 8-K on May 5, 2025, likely to announce its first-quarter financial results.

DEF 14A
DEF 14A
2025-03-28
10-K
10-K
2025-02-18
8-K
8-K
2025-02-18
8-K
FORM 8-K
2025-01-13
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
4 analysts
B. Riley Securities
2026-02-18
Maintains
Neutral Neutral
Piper Sandler
2026-02-18
Maintains
Overweight Overweight
BTIG
2026-02-18
Maintains
Buy Buy
Piper Sandler
2026-01-05
up
Neutral Overweight
Lake Street
2025-11-04
Maintains
Buy Buy
Piper Sandler
2025-11-04
reit
Neutral Neutral
BTIG
2025-11-04
up
Neutral Buy

Past News Coverage

Recent headlines mentioning TCMD from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile